Skip to menu Skip to content Skip to footer

2017

Conference Publication

Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry

Spelman, T., Schulz, M., Arora, B., Chung, E., Juneja, P., Walker, R., Verhaeghe, S., Butzkueven, H., Hodgkinson, S., Lechner-Scott, J., McCombe, P., Slee, M., Butler, E., Barnett, M., Skibina, O., Vucic, S., Macdonell, R., Shuey, N., Taylor, B. and Broadley, S. (2017). Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry. 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications.

Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry

2017

Conference Publication

Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Kalincik, T., Spelman, T., Jokubaitis, V., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Grammond, P., Alroughani, R., Lechner-Scott, J., Prevost, J., Terzi, M., Grand'Maison, F., Boz, C., Trojano, M., Van Wijmeersch, B., Pucci, E., Granella, F., Turkoglu, R., Sola, P., Ferraro, D., McCombe, P., Solaro, C., Van Pesch, V., Ozakbas, S., Slee, M. ... Butzkueven, H. (2017). Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404

Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

2017

Conference Publication

Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control Participants

Steyn, Frederik J., Restuadi, Restuadi, Ioannides, Zara, Ngo, Shyuan T., McRae, Allan, Wray, Naomi R., Henderson, Robert and McCombe, Pamela (2017). Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control Participants. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: BMJ. doi: 10.1136/jnnp-2017-316074.81

Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control Participants

2017

Conference Publication

Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study)

Coles, A. J., Boyko, A. N., De Seze, J., Hartung, H-P., Havrdova, E., Inshasi, J. S., McCombe, P., Montalban, X., Pozzilli, C., Selmaj, K. W., Vermersch, P., Margolin, D. H., Daizadeh, N., Rodriguez, C. E. and Van Wijmeersch, B. (2017). Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study). 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406

Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study)

2017

Conference Publication

The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis

Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Prat, A., Girard, M., Hupperts, R., Van Pesch, V., Ferraro, D., Alroughani, R., Bergamaschi, R., Pucci, E., Iuliano, G., Lechner-Scott, J., Spelman, T., Jokubaitis, V., Ramo-Tello, C., Spitaleri, D., Granella, F., Solaro, C., Ampapa, R., Deri, N., McCombe, P., Petersen, T., Van Wijmeersch, B., Prevost, J., Sanchez-Menoyo, J. L. ... Robsertson, N. (2017). The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731283

The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis

2017

Conference Publication

Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis

Merkel, Bernd, Jokubaitis, Vilija, Spelman, Tim, Lechner-Scott, Jeannette, McCombe, Pamela, Slee, Mark, Vucic, Steve, Skibina, Olga, Barnett, Michael, Hodgkinson, Suzanne, Butzkueven, Helmut and Kalincik, Tomas (2017). Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, May 09-12, 2017. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/jnnp-2017-316074.16

Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis

2017

Conference Publication

Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development program

Rog, D., Oh, J., Chambers, C., Hellwig, K., McCombe, P., Otero, S., Margolin, D. H., Daizadeh, N. and Compston, D. A. S. (2017). Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development program. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404

Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development program

2017

Conference Publication

Risk of secondary progressive multiple sclerosis: a longitudinal study

Fambiatos, A., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Izquierdo, G., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Alroughani, R., Terzi, M., Hupperts, R., Boz, C., Lechner-Scott, J., Pucci, E., Bergamaschi, R., Van Pesch, V., Ozakbas, S., Granella, F., Ramo, C., Turkoglu, R., Iuliano, G., Spitaleri, D. ... Kalincik, T. (2017). Risk of secondary progressive multiple sclerosis: a longitudinal study. 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications.

Risk of secondary progressive multiple sclerosis: a longitudinal study

2016

Journal Article

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

Tao, Chunrong, Simpson, Steve, van der Mei, Ingrid, Blizzard, Leigh, Havrdova, Eva, Horakova, Dana, Shaygannejad, Vahid, Lugaresi, Alessandra, Izquierdo, Guillermo, Trojano, Maria, Duquette, Pierre, Girard, Marc, Grand'Maison, Franois, Grammond, Pierre, Alroughani, Raed, Terzi, Murat, Oreja-Guevara, Celia, Sajedi, Seyed Aidin, Iuliano, Gerardo, Sola, Patrizia, Lechner-Scott, Jeannette, Van Pesch, Vincent, Pucci, Eugenio, Bergamaschi, Roberto, Barnett, Michael, Ramo, Cristina, Singhal, Bhim, Spitaleri, Daniele L. A., Slee, Mark ... Taylor, Bruce V. (2016). Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. JNNP Online, 87 (12), 1343-1349. doi: 10.1136/jnnp-2016-314013

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

2016

Journal Article

Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis

Xu, Zhouwei, Henderson, Robert David, David, Michael and McCombe, Pamela Ann (2016). Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS ONE, 11 (10) e0164625, e0164625. doi: 10.1371/journal.pone.0164625

Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis

2016

Journal Article

Defining secondary progressive multiple sclerosis

Lorscheider, Johannes, Buzzard, Katherine, Jokubaitis, Vilija, Spelman, Tim, Havrdova, Eva, Horakova, Dana, Trojano, Maria, Izquierdo, Guillermo, Girard, Marc, Duquette, Pierre, Prat, Alexandre, Lugaresi, Alessandra, Grand'maison, Francois, Grammond, Pierre, Hupperts, Raymond, Alroughani, Raed, Sola, Patrizia, Boz, Cavit, Pucci, Eugenio, Lechner-Scott, Jeanette, Bergamaschi, Roberto, Oreja-Guevara, Celia, Iuliano, Gerardo, Van Pesch, Vincent, Granella, Franco, Ramo-Tello, Cristina, Spitaleri, Daniele, Petersen, Thor, Slee, Mark ... Kalincik, Tomas (2016). Defining secondary progressive multiple sclerosis. Brain, 139 (9), 2395-2405. doi: 10.1093/brain/aww173

Defining secondary progressive multiple sclerosis

2016

Journal Article

Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression

Ioannides, Z. A., Ngo, S. T., Henderson, R. D., McCombe, P. A. and Steyn, F. J. (2016). Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression. Neurodegenerative Diseases, 15 (5-6), 382-397. doi: 10.1159/000446502

Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression

2016

Journal Article

Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort

Talman, Paul, Thi Duong, Vucic, Steve, Mathers, Susan, Venkatesh, Svetha, Henderson, Robert, Rowe, Dominic, Schultz, David, Edis, Robert, Needham, Merrilee, Macdonnell, Richard, McCombe, Pamela, Birks, Carol and Kiernan, Matthew (2016). Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open, 6 (9) e012054, e012054. doi: 10.1136/bmjopen-2016-012054

Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort

2016

Journal Article

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

Jokubaitis, Vilija G., Spelman, Tim, Kalincik, Tomas, Lorscheider, Johannes, Havrdova, Eva, Horakova, Dana, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Izquierdo, Guillermo, Grammond, Pierre, Van Pesch, Vincent, Pucci, Eugenio, Grand'Maison, Francois, Hupperts, Raymond, Granella, Franco, Sola, Patrizia, Bergamaschi, Roberto, Iuliano, Gerardo, Spitaleri, Daniele, Boz, Cavit, Hodgkinson, Suzanne, Olascoaga, Javier, Verheul, Freek, McCombe, Pamela, Petersen, Thor, Rozsa, Csilla, Lechner-Scott, Jeannette, Laura Saladino, Maria ... Trojano, Maria (2016). Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Annals of Neurology, 80 (1), 89-100. doi: 10.1002/ana.24682

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

2016

Journal Article

Interleukin 6 promoter 174 G/C polymorphisms in acute ischemic stroke: G allele is protective but not associated with IL-6 levels or stroke outcome

Yan, J., Greer, J. M. and McCombe, P. A. (2016). Interleukin 6 promoter 174 G/C polymorphisms in acute ischemic stroke: G allele is protective but not associated with IL-6 levels or stroke outcome. Journal of Neuroimmunology, 293, 22-27. doi: 10.1016/j.jneuroim.2016.02.001

Interleukin 6 promoter 174 G/C polymorphisms in acute ischemic stroke: G allele is protective but not associated with IL-6 levels or stroke outcome

2016

Journal Article

Contribution of different relapse phenotypes to disability in multiple sclerosis

Stewart, Tamasine, Spelman, Tim, Havrdova, Eva, Horakova, Dana, Trojano, Maria, Izquierdo, Guillermo, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Shaygannejad, Vahid, Hupperts, Raymond, Alroughani, Raed, Oreja-Guevara, Celia, Pucci, Eugenio, Boz, Cavit, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Van Pesch, Vincent, Iuliano, Gerardo, Ramo, Cristina, Taylor, Bruce, Slee, Mark, Spitaleri, Daniele, Granella, Franco, Verheul, Freek ... Kalincik, Tomas (2016). Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 23 (2), 266-276. doi: 10.1177/1352458516643392

Contribution of different relapse phenotypes to disability in multiple sclerosis

2016

Conference Publication

Pregnancy Outcomes in Patients with RRMS Who Received Alemtuzumab in the Clinical Development Program

Oh, Jiwon, Achiron, Anat, Chambers, Christina, Fox, Edward, McCombe, Pamela, Otero, Susana, Margolin, David, Kasten, Linda and Compston, D. Alastair (2016). Pregnancy Outcomes in Patients with RRMS Who Received Alemtuzumab in the Clinical Development Program. AAN 68th Annual Meeting, Vancouver, Canada, 15 - 21 April 2016. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.86.16_supplement.s24.008

Pregnancy Outcomes in Patients with RRMS Who Received Alemtuzumab in the Clinical Development Program

2016

Conference Publication

Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry

Kister, Ilya, Bacon, Tamar, Shaygannejad, Vahid, Hor, Jyh Yung, Alroughani, Raed, Haas, Shannon, Terzi, Murat, Boz, Cavit, Olascoaga, Javier, McCombe, Pamela, Fragoso, Yara, Lugaresi, Alessandra, Sola, Patrizia, Vucic, Steve, Pucci, Eugenio, Al-Harbi, Talal, Sajedi, Seyed Aidin, Rojas, Juan Ignacio, Patrucco, Liliana, Cristiano, Edgardo, Suarez, Jose Alberto, Tsolaki, Magdalini, Taylor, Bruce, Iuliano, Gerardo, Devranis, Paschalis, Marriott, Mark and Butzkueven, Helmut (2016). Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry. AAN 68th Annual Meeting, Vancouver, Canada, 15 - 21 April 2016. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.86.16_supplement.p5.307

Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry

2016

Journal Article

A case series of patients with autoimmune myasthenia gravis in association with invasive thymoma

McCombe, Pamela, Raj, Meenakshi, Henderson, Robert and Blum, Stefan (2016). A case series of patients with autoimmune myasthenia gravis in association with invasive thymoma. Journal of Clinical Neuromuscular Disease, 17 (3), 129-134. doi: 10.1097/CND.0000000000000101

A case series of patients with autoimmune myasthenia gravis in association with invasive thymoma

2016

Conference Publication

Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study

McCombe, P. A., Hartung, H-P, Havrdova, E., Selmaj, K. W., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2016). Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study. 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul South Korea, Nov 19-21, 2015. LONDON: SAGE PUBLICATIONS LTD.

Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study